Mondego Bio Reveals PTPN2 Inhibitor ZE00-0388 to Enter Clinical Trials by 2026 Mondego Bio has announced the selection of ZE00-0388 as their lead clinical candidate for a Phase 1 study commencing in H1 2026, focusing on PTPN2 inhibition.

Mondego Bio Reveals PTPN2 Inhibitor ZE00-0388 to Enter Clinical Trials by 2026 #Portugal #Mondego_Bio #Cantanhede #ZE00-0388 #PTPN2_Inhibitor